rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Organon & Co.

OGN · NYSE

Health CarePharmaceuticalsLeading

OGN stood above a rising 150-day average in 25 of the last 52 weekly readings, including each of the last 25 weeks. It is 10.0% above that average now. Pharmaceuticals: 34% of its 74 stocks in an uptrend (−5 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
25 in a row
Industry in uptrend
34% -5 in 4 wk
Insider buys, 12 months
$1.2M
Insider sales, 12 months
$1.1M
Officials’ trades on record
7
Institutions holding
580 (+21)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

22 Apr – 21 Oct
26%35%45%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$655K$0$655KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

7 disclosed lines: House 2, Senate 2, executive 3; 4 people.

WhoDidAmountTraded
Kevin Hern House: U.S. House ClerkOK01soldjoint$1k–$15k5 Aug 2026filed 12 Aug 2026
Kevin Hern House: U.S. House ClerkOK01soldjoint$1k–$15k5 Aug 2026filed 10 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k15 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k4 Mar 2026filed 14 May 2026
Gary C. Peters Senate: U.S. Senate eFDSenatorsold$1k–$15k10 Jul 2025filed 24 Nov 2025
John W. Hickenlooper Senate: U.S. Senate eFDSenatorsold$1k–$15k28 Jun 2021filed 9 Jul 2021

Insiders

Buy orders, 12 months2
Sale orders, 12 months2
Buyers · sellers2 · 2
WhoDidSharesTraded
Juliana Papa DrinaneHead of Mfg & Supplysold14,761at $13.575 Aug 2026filed 5 Aug 2026
Lynette HolzbaurSVP and Corporate Controllerbought26,448.366at $13.356 May 2026filed 7 May 2026
Lynette HolzbaurSVP and Corporate Controllersold26,448.366at $13.356 May 2026filed 7 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders580+21 on the quarter
New · exited118 · 99
Reported value$2.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202632,056,866$434.0M+339,838+1.1%
Pentwater Capital Management LPnew · filed 14 Aug 202618,100,000$245.1M+18,100,000
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 202615,132,118$204.9M-6,713,918−30.7%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202611,909,865$161.3M+172,847+1.5%
STATE STREET CORPreduced · filed 7 Aug 20269,659,371$130.8M-297,403−3.0%
KAHN BROTHERS GROUP INCunchanged · filed 14 Aug 20265,536,993$33.2M00.0%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 20265,199,002$70.4M+3,593,677+223.9%
UBS Group AGadded · filed 13 Aug 20264,856,529$65.8M+1,384,950+39.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,815,610$65.2M+56,273+1.2%
ALLIANCEBERNSTEIN L.P.added · filed 14 Aug 20264,754,671$28.5M+4,034,159+559.9%
31 Mar 2023 – 30 Jun 2026
563616669Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Ferreira Juan Camilo Arjona Company insiderHead of R&D & CMO · last 11 Aug 20260 · 0
Juliana Papa Drinane Company insiderHead of Mfg & Supply · last 5 Aug 20260 · 1
Kevin Hern HouseOK01 · last 5 Aug 20260 · 2
Donald J. Trump Executive branchWhite House Office · last 29 Jul 20261 · 2
Alan Ezekowitz Company insiderDirector · last 12 Jun 20260 · 0
Cynthia M. Patton Company insiderDirector · last 12 Jun 20260 · 0
Deborah R. Leone Company insiderDirector · last 12 Jun 20260 · 0
Helene D. Gayle Company insiderDirector · last 12 Jun 20260 · 0
Philip Ozuah Company insiderDirector · last 12 Jun 20260 · 0
Ramona Sequeira Company insiderDirector · last 12 Jun 20260 · 0
Robert Essner Company insiderDirector · last 12 Jun 20260 · 0
Rochelle B. Lazarus Company insiderDirector · last 12 Jun 20260 · 0

Same industry

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202553.3%
Free cash flow marginFY 2025 · to 31 Dec 20258.7%
Cash conversionFY 2025 · to 31 Dec 2025374%
Debt to equityFY 2025 · to 31 Dec 202511.52×
Share count trendFY 2025 · to 17 Feb 2026-0.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$574.0M
Free cash flowFY 2025 · to 31 Dec 2025$538.0M

Analyst forecasts

No analyst forecasts yet.